WHO to identify pathogens that could cause future outbreaks and pandemics
On Nov. 21, 2022, the WHO is launching a global scientific process to update the list of priority…
-
-
Peru reported first severe bird-flu outbreak
On Nov. 18, 2022, the World Health Organisation for Animal Health (WHO) announced that Peru had reported its…
-
Biotechnology | COVID-19 | Medicine | Vaccine
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster demonstrating improved immune response against Omicron sublineages
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Biotechnology | Diagnostics | Non-Profit Research | Oncology | Therapeutics | Vaccine | Women's Health
CPRIT approved $12 million to bring top-flight cancer researchers to Lone Star State
On Nov. 16, 2022, the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment…
-
Roche received U.S. FDA Emergency Use Authorization for its high-throughput test to detect mpox virus
On Nov. 15, 2022, Roche announced that the U.S. Food and Drug Administration (FDA) had granted Emergency Use…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
-
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
-
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
-
USDA confirmed highly pathogenic Avian influenza in commercial chickens in Mississippi
On Nov. 5, 2022, the U.S. Department of Agriculture’s (USDA) Animal Plant Health Inspection Service (APHIS) confirmed the…
-
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
-
University of Missouri study found Mpox mutations caused virus to spread rapidly, evade drugs and vaccines
On Nov. 3, 2022, researchers have identified the specific mutations in the mpox virus that contribute to its…
-
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
-
Pfizer announced positive top-line data of phase 3 global trial for bivalent RSV vaccine candidate
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
-
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
-
INOVIO Discontinued internal efforts to develop INO-4800 as COVID-19 heterologous booster vaccine Candidate
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Nanotechnology | Therapeutics | Vaccine
COVID-causing virus in air detected with high-tech bubbles
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
-
Study confirmed safety of shingles vaccine
On Oct. 20, 2022, published results supported previous findings that the recombinant zoster vaccine Shingrix, recommended by the…
-
Biotechnology | HIV | NIH | Vaccine
Three-dose hepatitis B vaccine regimen protected people with HIV
On Oct. 20, 2022, the National Institutes of Health announced that a three-dose course of the hepatitis B…
-
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization…
-
EMA’s CHMP for Human Use issued positive opinion recommending authorization for use of Spikevax in children 6 months – 5 years in EU
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
-
Biotechnology | Diagnostics | Infectious Disease | Polio | Vaccine | WHO
Global leaders committed US$ 2.6 billion at World Health Summit to end polio
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
-
Moderna announced supply agreement with Gavi that secured access to updated variant-specific COVID-19 vaccines for low-and-middle income countries
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, a biotechnology company pioneering messenger RNA (mRNA) therapeutics…
-
Novavax COVID-19-influenza combination vaccine candidate induced antibody and T-Cell responses against SARS-CoV-2 and influenza
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
-
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
-
Gene associated with better immune response and protection after COVID-19 vaccination identified by Oxford researchers
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
-
Moderna received Authorization for Emergency Use from FDA of Omicron-targeting bivalent COVID-19 booster vaccine for children
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
-
Biotechnology | CDC | COVID-19 | FDA | Infectious Disease | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
